Sun Pharmaceutical Industries Ltd gets import alert for Halol facility

Sun Pharmaceutical Industries Limited had earlier announced regarding the USFDA inspection at the Company's Halol (Gujarat) facility from April 26 to May 9, 2022.

The Company has received a communication from the USFDA stating that the facility has been listed under Import Alert. The Import Alert implies, that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with cGMP standards. The USFDA has excluded 14 products from this Import Alert subject to certain conditions.

For the year ended 31-March-2022, supplies to the US market from the Halol facility accounted for approximately 3% of the Company's consolidated revenues, including the 14 excluded products as mentioned above. The Company continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company's remedial action.

Sun Pharma remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1033.25 as compared to the previous close of Rs. 1037.50. The total number of shares traded during the day was 11695 in over 851 trades.

The stock hit an intraday high of Rs. 1038.80 and intraday low of 1023.35. The net turnover during the day was Rs. 12031087.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 USFDA ImportAlert HalolFacility